Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 1
Submit an article Journal homepage
4,823
Views
20
CrossRef citations to date
0
Altmetric
Psoriasis and atopic dermatitis

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

Lajos KeményMTA SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary; ;Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary; Correspondence[email protected]
View further author information
,
Lovisa BerggrenLilly Deutschland GmbH, Bad Homburg, Germany; View further author information
,
Martin DossenbachLilly Deutschland GmbH, Bad Homburg, Germany; View further author information
,
Yves DutroncEli Lilly and Company, Indianapolis, IN, USA; View further author information
&
Carle PaulDepartment of Dermatology, Paul Sabatier University and CHU Toulouse, Toulouse, FranceView further author information
Pages 19-26 | Received 10 Apr 2018, Accepted 24 Apr 2018, Published online: 12 Jun 2018

References

  • Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
  • Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
  • Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (Basel). 2005;210:194–199.
  • Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. 2004;15:27–29.
  • Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158–165.
  • National Institute for Health and Clinical Excellence. Psoriasis: the management of psoriasis [Internet]. London: National Institute for Health and Clinical Excellence; 2012 [cited 2018 May 14]. Available from: https://www.nice.org.uk/guidance/cg153/documents/psoriasis-nice-guideline2
  • European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis [Internet]. London: European Medicines Agency; 2004 [cited 2018 May 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf
  • Ponnambath N, Kalavala M, Anstey AV, et al. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20. Clin Exp Dermatol. 2016;41:95–96.
  • Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudi-nal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74:851–861.
  • Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31:679–685.
  • Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)). J Am Acad Dermatol. 2017;77:855–862.
  • Schafer JL. Analysis of incomplete multivariate data. New York (NY): Chapman and Hall; 1997.
  • Rubin DB. Multiple imputation for nonresponse in surveys. New York (NY): John Wiley & Sons, Inc; 1987.
  • Hägg D, Eriksson M, Sundström A, et al. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One. 2013;8:e63619.
  • Hägg D, Sundström A, Eriksson M, et al. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18:583–590.
  • van de Kerkhof P, Murphy GM, Austad J, et al. Psoriasis of the face and flexures. J Dermatolog Treat. 2007;18:351–360.
  • Young Park J, Hyun Rim J, Beom Choe Y, et al. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004;50:582–584.
  • Tabolli S, Paradisi A, Giannantoni P, et al. Factors associated with the prescription of “traditional” or “biological” systemic treatment in psoriasis. J Dermatolog Treat. 2015;26:37–40.
  • Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176–1182.
  • Strober B, Leonardi C, Papp K, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432–440.
  • Gefland JM, Neimann AL, Wang X, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741.
  • Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173–1179.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.